ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[PRL]
GO:0040014;regulation of multicellular organism growth;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;36.77819272999274;5.557565922504363;0.0012309330124483187;0.5744551915910391;[PRL]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[LHCGR, NASP]
GO:0033141;positive regulation of peptidyl-serine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;940.2079225453168;6.781341354126479;0.03146791303539702;0.7792270645443136;[IFNA5, IFNA4, IFNA7, IFNA14, IFNA16, IFNA2, IFNA8, IFNA21, IFNA10]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[CDC6, SKP2, PRL, MEIS2]
GO:0045762;positive regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6276.064729494611;7.697632086000634;0.21005423840463325;0.8417775754447168;[LHCGR]
GO:0007595;lactation;6.0;1.0;0.8231203125901445;9.628524252492122;25.956233089099676;5.9928839937622085;8.687317623989867E-4;0.6295966787287501;[PRL]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[PRL]
GO:1903489;positive regulation of lactation;7.0;0.9326813400603323;0.8172600352873667;9.571365838652174;160.4352972466691;8.67846133901236;0.005369625016452592;0.7947362817240173;[PRL]
GO:0042531;positive regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1230.2749798860389;5.618190544320798;0.04117619640118775;0.7197434780388068;[IFNA2]
GO:0002286;T cell activation involved in immune response;6.0;0.6997970393407541;0.6730188322605215;8.890925309361343;82.05045983278045;5.845247994956144;0.002746155049983451;0.6220465668840318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, IFNA21, IFNA14, IFNA16, IFNA10]
GO:0042699;follicle-stimulating hormone signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;62.84085921303097;8.16763571524637;0.002103227004758593;0.7408135829017477;[LHCGR]
GO:0009755;hormone-mediated signaling pathway;5.0;0.6519675769143192;0.6162248003180799;7.98629651723503;23.17027026302992;4.61801832846594;7.75488093814194E-4;0.5264066839384828;[NR3C2, LHCGR]
GO:0071373;cellular response to luteinizing hormone stimulus;8.0;1.0;0.875;9.628524252492122;601.1788189541068;8.67846133901236;0.020120914044583264;0.8188169164668168;[LHCGR]
GO:0001545;primary ovarian follicle growth;3.0;0.8933024483968273;0.6447715367885581;9.292052015870908;21.717098748465986;8.67846133901236;7.268517509911946E-4;0.6419372290569613;[LHCGR]
GO:0045892;negative regulation of transcription, DNA-templated;10.0;0.556709148698489;0.6935955862101648;8.520155788878647;1581.2569993850602;2.683669001811703;0.05292324873051003;0.5524839694169422;[EZH2, GMNN, TLE4, RFC1, E2F7, IFNA2, ARID4A, HMGA1, MEIS2]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[ATAD2, E2F7, HMGA1, RFC1, IFNA2, PRL, ARID4A, MEIS2]
GO:0043330;response to exogenous dsRNA;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;30.956451235720028;5.970411137910149;0.0010360845638621964;0.6284474158353811;[IFNA5, IFNA4, IFNA7, IFNA14, IFNA16, IFNA2, IFNA8, IFNA21, IFNA10]
GO:0045670;regulation of osteoclast differentiation;8.0;0.8259837884571596;0.7879918942285797;9.485423408851448;139.67875005531917;5.587418885654044;0.0046749220616377945;0.6607408616538982;[LHCGR]
GO:0051607;defense response to virus;6.0;0.8653626801206646;0.7558016526504768;9.485423408851448;78.89111305633469;4.573066940603674;0.0026404145566033123;0.5569871686019774;[IFNA14, IFNA16, IFNA10, IFNA21, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8]
GO:0032962;positive regulation of inositol trisphosphate biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;985.0638483814348;8.16763571524637;0.03296920050541953;0.8139338954918922;[LHCGR]
GO:2000552;negative regulation of T-helper 2 cell cytokine production;10.0;1.0;0.9152410118609203;9.628524252492122;875.747891014041;8.390779266560578;0.029310493790307247;0.8443458537639685;[IFNA2]
GO:0060397;JAK-STAT cascade involved in growth hormone signaling pathway;8.0;1.0;0.875;9.628524252492122;26.42836680105094;7.212124270218933;8.845336528452411E-4;0.7438283705770736;[PRL]
GO:0030183;B cell differentiation;6.0;0.7307253602413294;0.6884829927108091;9.022388448921806;64.35544597283358;5.2552850506314295;0.0021539188605695985;0.5918758344751833;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, IFNA14, IFNA16, IFNA10, IFNA21]
GO:0044267;cellular protein metabolic process;5.0;0.3358520568840654;0.45816704030295297;5.574370570853267;80.86766357206795;1.6585685600933726;0.0027065679235849286;0.3750602851554211;[PKMYT1, PCNA, CIT, PRL, HIST1H2BK, WEE1, EZH2, MELK, SKP2, MAP4K1, ARID4A]
GO:0042100;B cell proliferation;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;50.60132884827668;6.166155715036245;0.00169358093831245;0.6384578026126634;[IFNA5, IFNA4, IFNA7, IFNA14, IFNA16, IFNA2, IFNA8, IFNA21, IFNA10]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[PRL]
GO:0007166;cell surface receptor signaling pathway;5.0;0.43360584258713153;0.507043933154486;5.906854975555195;23.17027026302992;2.006850423521684;7.75488093814194E-4;0.39287143584790796;[IFNA14, IFNA16, IFNA10, IFNA21, STMN1, TLE4, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[LHCGR]
GO:0007200;phospholipase C-activating G-protein coupled receptor signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.976932752798508;5.288437257948329;9.028936615729279E-4;0.5935712398991049;[LHCGR]
GO:0009967;positive regulation of signal transduction;6.0;0.44130843764162375;0.5437745314109563;6.712834686611667;140.23187634019237;2.4492930892588385;0.004693434700611163;0.44837727507861835;[EZH2, ARHGAP6, ADAMTS20, SKP2, IFNA2, PRL, MAP4K1]
GO:0045636;positive regulation of melanocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;190.69673191605972;8.390779266560578;0.006382448001314043;0.7800242071602487;[ADAMTS20]
GO:0060337;type I interferon signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;5.587418885654044;0.00101047745553359;0.6366602269110988;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, IFNA21, IFNA14, IFNA16, IFNA10]
GO:0042700;luteinizing hormone signaling pathway;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;26.976932752798508;8.67846133901236;9.028936615729279E-4;0.7669372290569613;[LHCGR]
GO:0046427;positive regulation of JAK-STAT cascade;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;286.6013214379199;5.459585514144159;0.009592288304083759;0.675444082270312;[IFNA2, PRL]
GO:0002323;natural killer cell activation involved in immune response;6.0;0.8653626801206646;0.7558016526504768;9.387362195675234;81.35731265221925;6.641579411751319;0.0027229560376420305;0.6627709925721352;[IFNA5, IFNA4, IFNA7, IFNA14, IFNA16, IFNA2, IFNA8, IFNA21, IFNA10]
GO:0045581;negative regulation of T cell differentiation;9.0;0.7043150770688792;0.7483981637147287;9.320222892837606;878.9850552837634;6.088194173566533;0.029418838765156156;0.7075911583464645;[IFNA2]
GO:0030539;male genitalia development;5.0;1.0;0.7902410118609202;9.628524252492122;66.31594138202881;6.832634648514029;0.002219534877584045;0.639662265535933;[LHCGR]
GO:0046597;negative regulation of viral entry into host cell;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.95196338807416;6.832634648514029;0.002843265762795464;0.7244212536750128;[IFNA2]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, IFNA14, IFNA16, IFNA10, IFNA21, HIST1H2BK]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[UNG, ADAMTS20]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[ADAMTS20, SKP2, RANBP1]
GO:2000666;negative regulation of interleukin-13 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.9724324201893;8.67846133901236;0.02523477878196853;0.8590579283277371;[IFNA2]
GO:0001937;negative regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.36028873802138;6.193554689224359;0.002923870244906099;0.6676580400938822;[PRL]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[IFNA14, IFNA16, IFNA10, IFNA21, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8]
GO:2000663;negative regulation of interleukin-5 secretion;10.0;1.0;0.9152410118609203;9.628524252492122;753.9724324201893;9.083926447120524;0.02523477878196853;0.8797934328124444;[IFNA2]
